Semaglutide or Tirzepatide Added to Psychological Support in Binge Eating Disorder With Overweight or Obesity: The LEAP ‐ BED Prospective Pilot Study

The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.71510. Figure S1: (a, b) Individual Binge Eating Scale (BES) trajectories from baseline to follow-up in the AOM + PS group (n = 29) and the PS-alone group (n = 12); the dashed line marks the BES = 17 threshold and thick lines are group means. (c) Response rates with 95% confidence intervals for the overall AOM group, controls and the semaglutide and tirzepatide subgroups. Response was defined a priori as a follow-up BES < 17 or a reduction of at least 50% from baseline; the AOM-versus-control difference was borderline (Fisher p = 0.052) and the semaglutide-versus-tirzepatide difference was non-significant (Fisher p = 0.63). (d) Mean percentage change from baseline (T1–T0) for anthropometric, behavioural and metabolic measures in each group; blue indicates a decrease and red an increase. AOM, anti-obesity medication; AST/ALT, aminotransferases; GGT, gamma-glutamyl transferase; HOMA-IR, homeostatic model assessment of insulin resistance; PS, psychological support; TG, triglycerides. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.